by EPI Health | Jul 19, 2021 | Press Release
PRESS RELEASE for distribution July 19, 2021, 08:00 ET Now available: Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age or older introduces use of PAD™...
by EPI Health | Jul 12, 2021 | Press Release
PRESS RELEASE for distribution July 6, 2021 Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) vs Taclonex® Topical Suspension were shown at the Maui Derm NPPA Summer meeting...
by EPI Health | Nov 4, 2020 | Press Release
NEWS PROVIDED BY EPI Health, LLC November 4, 2020 The formulary at Express Scripts and other major PBMs have expanded coverage to include Rhofade® and other EPI Health Products, bringing coverage to over 145 million US Commercial lives. Rhofade®...
by EPI Health | Sep 20, 2020 | Press Release
Express Scripts National Preferred Formulary covers approximately 24 million lives — Rhofade® is the only FDA-approved alpha 1 agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults CHARLESTON,...
by EPI Health | Aug 26, 2020 | Press Release
Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in...
Recent Comments